Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
PR94936
BEIJING and BRIDGEWATER, N.J., Mar 10, 2022, /PRNewswire=KYODO JBN/--
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee,
stock code: 603087.SH), is pleased to announce the first subject has been dosed
in our Phase I, double-blinded, randomized, placebo-controlled, sequential,
single, ascending dose clinical study in the U.S. for the company’s
investigational drug, GZR18. GZR18 is a glucagon-like peptide-1 receptor
agonist (GLP-1RA) with potential to treat patients with type 2 diabetes.
Currently, type 2 diabetes mellitus accounts for approximately 90% of all
diabetes cases while a 46% increase in the number of people with diabetes is
expected by 2045, globally[1]. Glucagon-like peptide-1 (GLP-1) is an incretin
hormone responsible for many glucoregulatory effects such as the stimulation of
insulin secretion and the inhibition of glucagon when blood glucose is high[2].
Many of these glucoregulatory effects are often impaired in patients with type
2 diabetes[3].
The primary objective of this Phase 1 study is to investigate the safety and
tolerability of GZR18 in healthy volunteers. In addition, the secondary
objective is to determine the pharmacokinetic (PK) parameters of GZR18. “The
start of this Phase 1 clinical trial of GZR18 at a U.S. site, is a significant
milestone for our global clinical development program. This trial demonstrates
Gan & Lee’s long-term commitment to strengthening our pipeline in diabetes and
other therapeutic areas to benefit the patient and medical community” said Dr.
Mike Hu, the Chief Executive Officer (CEO) & President of Gan & Lee
Pharmaceuticals USA Corporation.
About Gan & Lee
Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic
human insulin. Currently, we have five recombinant insulin analogs
commercialized in China including long-acting glargine injection (Basalin®),
fast-acting lispro injection (Prandilin™), fast-acting aspart injection
(Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin®25), aspart
30 injection (Rapilin®30), and one human insulin injection - mixed protamine
human insulin injection (30R) (Similin®30). We have two approved medical
devices in China, namely reusable insulin injection pen (GanleePen™), and
disposable pen needle (GanleeFine®).
In the future, Gan & Lee strives to achieve a comprehensive coverage in the
field of diabetes diagnosis and treatment. Moving forward to advance our goal
of becoming a world-class pharmaceutical company, we will also take an active
part in developing new chemical entities, and work on the treatment of
cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.
For more information, please contact us at investorrelations@ganlee.us.
References
[1]. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels,
Belgium: 2021. Available at: https://www.diabetesatlas.org
[2]. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the
treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;
46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776;
PMCID: PMC8085572. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/
[3]. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2
diabetes: role and clinical experience to date. Postgrad Med. 2020
Nov;132(sup2):3-14. doi: 10.1080/00325481.2020.1798099. Epub 2020 Sep 8. PMID:
32815454.
Media Contacts: Gina Antonucci, #: 888-288-5395, investorrelations@ganlee.us
Source: Gan & Lee Pharmaceuticals Co., Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。